Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

证券日报网讯 12月28日，申联生物发布公告称，童光志因个人原因申请辞去公司董事职务，同时一并 辞去在公司董事会下设的战略委员会、提名委员会中担任的委员职务，辞任后不在公司担任何职务；聂 文豪因工作调整申请辞去公司副总经理职务，辞任后仍在公司担任董事一职，并在公司及子公司担任其 他职务。2025年12月25日，公司召开职工代表大会，选举张震为公司第四届董事会职工代表董事。公司 第四届董事会第六次会议选举职工代表董事张震先生为公司第四届董事会提名委员会委员和第四届董事 会战略委员会委员。 （编辑 王江浩） ...

（文章来源：证券日报） 证券日报网讯 12月28日，申联生物发布公告称，公司拟续聘容诚会计师事务所（特殊普通合伙）为 2025年度财务报告及内控审计机构，聘期一年，审计费用57万元，其中财务报告审计费45万元，较上年 度下降6.25%，内控审计费12万元不变，该议案已获董事会通过，尚待股东会审议。 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-044 申联生物医药（上海）股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 12 月 27 日召开第四届董事会第六次会议，审议通过了《关 于续聘会计师事务所的议案》，公司拟续聘容诚会计师事务所（特殊普通合伙） （以下简称"容诚会计师事务所"）为公司 2025 年度财务报告和内部控制审计机 构，聘期一年。现将相关事项公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 截至2024年12月31日，容诚会计师事务所共有合伙人196人，共有注册会计 师1549人，其中781人签署过证券服务业务审计报告。 3、业务规模 1、基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于1988年8月，2013年12月10日改制为特殊普通合伙 企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证券服 务业务。注册地址为北京市西城 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会于近日收到公司董事童光志先生、副总经理聂文豪先生递交 的书面辞职报告。童光志先生因个人原因申请辞去公司董事职务，同时一并辞去 在公司董事会下设的战略委员会、提名委员会中担任的委员职务，辞任后不在公 司担任何职务；聂文豪先生因工作调整申请辞去公司副总经理职务，辞任后仍在 公司担任董事一职，并在公司及子公司担任其他职务。根据《中华人民共和国公 司法》（以下简称"《公司法》"）《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》"）等法律法规及《申联生物医药（上海）股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，童光志先生和聂文豪先生的 辞职报告自送达董事会之日起生效。 证券代码：688098 证券简称：申联生物 公告编号：2025-045 申联生物医药（上海）股份有限公司 关于公司董事、高级管理人员离任暨选举职工代表董 事、补选董事会专门委员会委员的公告 二、职工代表董事选举情况 根据《公司法》《上海证券交易所上市公司自律监管指引第 1 ...

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Group 1 - China Shenhua plans to issue A-shares and pay cash to acquire assets from its controlling shareholder, China Energy Group, and its wholly-owned subsidiary, West Energy, for a total transaction price of 133.598 billion yuan, with 30% paid in shares and 70% in cash [1][4] - Qingdao Port intends to invest approximately 15.7 billion yuan in two terminal projects [4] - Jifeng Co., Ltd. has been awarded a total assembly project for passenger car seats, with an estimated total lifecycle value of 9.8 billion yuan [4] Group 2 - Shengxin Lithium Energy's partner, Zhongxin Aviation, plans to purchase 200,000 tons of lithium salt products from the company between 2026 and 2030 [4] - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in an advanced materials supporting waste salt comprehensive utilization project [4] - Tianqi Lithium's third-phase chemical-grade lithium concentrate expansion project has been completed and is now in trial operation [4] Group 3 - Oriental Cable has recently won projects totaling approximately 3.125 billion yuan [4] - Jiangshan Luneng has signed a series of contracts totaling approximately 815 million yuan [4] - Huahai Wenkang has produced over 800 CMP equipment units [4] Group 4 - Sichuan Chengyu's subsidiary plans to acquire 85% of Jingyi Company for 2.409 billion yuan [4] - Qi Yi Er intends to acquire 60% of Fangzhou Technology through acquisition and capital increase [4] - Tianchuang Fashion is planning a change of control, resulting in a stock suspension [4]

据天眼查APP显示，申联生物医药(上海)股份有限公司成立于2001年06月28日，注册资本41064.4万人民 币。（数据宝） 12月19日申联生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | | | | | 中信建投证券股份有 | 国信证券股份有限公司上海 | | 205.30 | 1806.64 | 8.80 | -2.33 | 限公司广西分公司 | 陆家嘴环路证券营业部 | （文章来源：证券时报网） 申联生物12月19日大宗交易平台出现一笔成交，成交量205.30万股，成交金额1806.64万元，大宗交易成 交价为8.80元，相对今日收盘价折价2.33%。该笔交易的买方营业部为中信建投证券股份有限公司广西 分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。 证券时报·数据宝统计显示，申联生物今日收盘价为9.01元，上涨2.15%，日换手率为0.63 ...

Core Viewpoint - The company Shenyuan Biotech (688098.SH) announced that its affiliate Yangzhou Shizhi Source Biotechnology Co., Ltd. has received a patent from the National Intellectual Property Administration for a novel treatment method for HIV infection using monoclonal antibodies targeting CD4 [1] Group 1: Patent and Technology - The patent pertains to a method for treating and functionally curing HIV infection through monoclonal antibodies that target CD4, including their compositions and usage [1] - The drug UB-421, under development by Shizhi Source, has a unique mechanism of action that effectively blocks HIV from entering host cells by competitively binding to the CD4 receptor on T cells [1] Group 2: Market Implications - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing HIV treatments, as it does not directly target viral genes [1] - The drug will primarily focus on areas such as multi-drug resistance and functional cure in the domestic market [1]